Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy

The blockade of programmed cell death protein 1 (PD-1) as monotherapy has been widely used in melanoma, but to identify melanoma patients with survival benefit from anti-PD-1 monotherapy is still a big challenge. There is an urgent need for prognostic signatures improving the prediction of immunothe...

Full description

Bibliographic Details
Main Authors: Jian-Guo Zhou, Bo Liang, Jian-Guo Liu, Su-Han Jin, Si-Si He, Benjamin Frey, Ning Gu, Rainer Fietkau, Markus Hecht, Hu Ma, Udo S. Gaipl
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cells
Subjects:
lncRNA
advanced melanoma
predictor
survival benefit
immune checkpoint inhibitor
PD-1
Online Access:https://www.mdpi.com/2073-4409/10/5/977

Similar Items

Similar Items